

What is claimed is:

1. A T cell receptor (TCR) polypeptide having antigenic specificity for human papillomavirus (HPV) 16 (HPV16), wherein the TCR comprises at least one complementary determining region 3 α (CDR3 α) amino acid sequence and at least one CDR3 β amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs:13 to 52, or 219 to 226.
2. A TCR polypeptide having antigenic specificity for HPV16, wherein the TCR is specific for antigens comprising at least one epitope having an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 1 to 12, 217 or 218.
3. The TCR polypeptide of claim 1 or claim 2, wherein the TCR has antigenic specificity for HPV16 peptides other than E6 and E7, and/or the TCR has antigenic specificity for any one of HPV16 peptides E1, E2, E4, or E5.
4. The TCR polypeptide of claim 3, wherein the TCR comprises a CDR3 α amino acid sequence and CDR3 β amino acid set forth in SEQ ID NOs: 13 and 14, SEQ ID NOs: 25 and 26, SEQ ID NOs: 51 and 52, SEQ ID NOs: 60 and 59 or SEQ ID NOs: 62 and 61.
5. A nucleic acid encoding the TCR polypeptide of any one of claims 1 to 4.
6. An immune cell comprising one or both of the nucleic acid of claim 5 and the TCR polypeptide of any one of claims 1 to 4.
7. The immune cell of claim 6, wherein the immune cell is a lymphocyte selected from an $\alpha\beta$ T cell, $\gamma\delta$ T cell, a Natural Killer (NK) cell, a Natural Killer T (NKT) cell, a B cell, an innate lymphoid cell (ILC), a cytokine induced killer (CIK) cell, a cytotoxic T lymphocyte (CTL), a lymphokine activated killer (LAK) cell, a regulatory T cell, or any combination thereof.
8. The immune cell of claim 6 or claim 7, wherein the immune cell is a cytotoxic T lymphocyte (CTL).
9. The immune cell of claim 8, wherein the immune cell is a CTL sensitized to a viral antigen from any one of human papilloma virus (HPV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), B.K. virus (BKV), John Cunningham virus (JCV), picornavirus (e.g., Hepatitis A virus), hepadnavirus (e.g., Hepatitis B virus), hepacivirus (e.g., Hepatitis C virus), deltavirus (e.g., Hepatitis D virus), hepevirus (e.g., Hepatitis E virus), or any combination thereof.
10. The TCR-expressing cell of any one of claims 7 to 9, wherein the TCR-expressing cell:
 - is genetically modified to no longer express one or more immune checkpoint molecules (e.g., PD-1 and/or CTLA-4); and/or
 - expresses a dominant-negative form of one or more immune checkpoint molecules; and/or
 - expresses switch receptors specific for one or more immune checkpoint molecules; and/or;

- expresses antibodies, or functional fragments thereof, capable of blocking signaling by one or more checkpoint molecules.
11. The use of an adoptive immunotherapy composition for the manufacture of a medicament for the treatment of a HPV-associated cancer or precancerous lesions in a subject, the adoptive immunotherapy composition comprising the TCR-expressing cells of any one of claims 6 to 10.
 12. The use of claim 11, wherein the HPV-associated cancer is a squamous cell carcinoma.
 13. The use of claim 11 and claim 12, wherein the subject has received, is receiving, or will receive an additional anti-cancer therapy (for example, surgery, radiation, chemotherapy, immunotherapy, or hormone therapy), and optionally wherein the subject has received IFN γ prior to administering the adoptive immunotherapy composition.
 14. The use of any one of claims 11 to 13, wherein the TCR-expressing cells of the adoptive immunotherapy composition are derived from the subject or are derived from a donor sample, or from a bank or library of donor samples.
 15. The use of any one of claims 11 to 14, further comprising administering at least one immune checkpoint inhibitor.
 16. The use of claim 15, wherein the immune checkpoint inhibitor comprises an anti -PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CTLA-4 antibody, or a combination thereof.
 17. The use of claim 15, wherein the immune checkpoint inhibitor comprises an RNAi molecule such as an antisense RNA molecule (asRNA), micro RNA molecule (miRNA), short hairpin RNA molecule (shRNA), or small interfering RNA molecule (siRNA).
 18. The use of claim 15, wherein the immune checkpoint inhibitor comprises a CRISPR RNA (crRNA) molecule, or a dominant negative form of an immune checkpoint molecule, or a recombinant switch receptor.
 19. A cell bank comprising cells for adoptive immunotherapy, wherein the cells are the TCR-expressing cells of any one of claims 6 to 9, and wherein the HLA restriction of the TCR-expressing cells is known.